Lindbrook Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Lindbrook Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$7.25K	Buy	69 +6	+10%	+$679	﹤0.01%	1793
2024 Q4	$6.75K	Hold	63	–	–	﹤0.01%	1845
2024 Q3	$6.31K	Hold	63	–	–	﹤0.01%	1908
2024 Q2	$5.31K	Buy	63 +8	+15%	+$637	﹤0.01%	1965
2024 Q1	$4.02K	Hold	55	–	–	﹤0.01%	1993
2023 Q4	$3.93K	Buy	+55	New	+$3.25K	﹤0.01%	2012
2023 Q3	–	Sell	-20	Closed	-$1.44K	–	2766
2023 Q2	$1.44K	Hold	20	–	–	﹤0.01%	2279
2023 Q1	$1.47K	Buy	+20	New	+$1.42K	﹤0.01%	2360
2022 Q4	–	Sell	-93	Closed	-$5K	–	2925
2022 Q3	$5K	Buy	+93	New	+$5.47K	﹤0.01%	1676
2020 Q2	–	Sell	-30	Closed	-$1K	–	1813
2020 Q1	$1K	Hold	30	–	–	﹤0.01%	1493
2019 Q4	$2K	Hold	30	–	–	﹤0.01%	1298
2019 Q3	$2K	Sell	30 -92	-75%	-$5.78K	﹤0.01%	1274
2019 Q2	$8K	Hold	122	–	–	﹤0.01%	951
2019 Q1	$9K	Hold	122	–	–	﹤0.01%	927
2018 Q4	$10K	Buy	+122	New	+$13K	﹤0.01%	823

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's LGND Position: Q1 2025 in Review

Lindbrook Capital increased its Ligand Pharmaceuticals (LGND) stake by 9.5% in Q1 2025, buying an estimated $679 and bringing the position to 69 shares worth $7.25K. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Lindbrook Capital first reported a position in LGND in Q4 2018 and has held it in 15 quarters since. The position peaked at $10K in Q4 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

Lindbrook Capital held 69 shares of Ligand Pharmaceuticals worth $7.25K as of Q1 2025.
Lindbrook Capital bought 6 Ligand Pharmaceuticals shares in Q1 2025, an estimated $679.
Ligand Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1793 holding.
Lindbrook Capital first reported a position in Ligand Pharmaceuticals in Q4 2018 and has held it in 15 quarters since.
Lindbrook Capital's Ligand Pharmaceuticals position peaked at $10K in Q4 2018.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.